AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$KRRO

FORMELA JEAN FRANCOIS sold $974K of KRRO (indirect holdings)

FORMELA JEAN FRANCOIS sold 66,632 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $14.61 ($14.30–$15.60, $0.97M total) across 6 trades over 2026-11-11 to 2026-11-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FORMELA JEAN FRANCOIS
Published Nov 13, 2026, 10:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KRRO
Bearish
high confidence
Mentioned
$KRRO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KRROBearishLow
01

Why it matters

The disclosed sale may prompt short‑term selling pressure, but the retained stake suggests continued confidence.

02

Market read

Primary insider sale for a micro‑cap biotech; modest trading relevance.

03

What to watch

The director retains a sizable stake (121,219 shares) and the sale price was near recent market levels.

Relevance 4/10Novelty 4/10Timing: after-hours filing on 2026-11-13

Background

SEC Form 4 filings disclose insider transactions. This filing reports a director's open‑market sale of KRRO shares.

Company-level read

Ticker impact

$KRROBearishHigh confidence
Context

Director Jean Francois Formela sold 66,632 shares of Korro Bio for $973,609, reducing his stake to 121,219 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A 10b5-1 planned sale by a director of nearly $1M is material for a micro‑cap biotech and often leads to short‑term downside.

Market effects

Sector

Minimal; biotech sector may see slight caution but no broader impact.

Regional

None; the filing is company‑specific.

Global

Low; only relevant to KRRO investors.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event under a 10b5-1 plan, not a negative signal.

Key entities

  • Company
    Korro Bio, Inc.

    Biotech company developing RNA‑based therapeutics, ticker KRRO.

  • Insider
    Jean Francois Formela

    Director of Korro Bio who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KRRO insider trading history →

Related articles

$KRROMedAI 8/10

Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency • Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating function

SEC EDGAR 8-K
$KRROMedAI 8/10

H.C. Wainwright reiterates Korro Bio stock rating on trial dosing

H.C. Wainwright reiterated a Buy rating and $15.00 price target for Korro Bio (KRRO) after the company dosed the first cohort in its Phase 1/2 trial for KRRO-121. The stock is down 77% over the past year, trading at $9.97. Korro Bio has a strong current ratio of 9.55 and more cash than debt. The ANCHOR trial is expected to take about a year, with primary completion estimated for the second half of 2027.

investing.com